These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 4562819)

  • 1. Rifampin: a semisynthetic derivative of rifamycin--a prototype for the future.
    Lester W
    Annu Rev Microbiol; 1972; 26():85-102. PubMed ID: 4562819
    [No Abstract]   [Full Text] [Related]  

  • 2. Chemical and biological properties of rifampicin.
    Furesz S
    Antibiot Chemother; 1970; 16():316-51. PubMed ID: 5002304
    [No Abstract]   [Full Text] [Related]  

  • 3. Rifampicin: a review.
    Drugs; 1971; 1(5):354-98. PubMed ID: 4949280
    [No Abstract]   [Full Text] [Related]  

  • 4. Antibacterial activity of DL 473, a new semisynthetic rifamycin derivative.
    Arioli V; Berti M; Carniti G; Randisi E; Rossi E; Scotti R
    J Antibiot (Tokyo); 1981 Aug; 34(8):1026-32. PubMed ID: 7319918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rifampicin.
    Polascik M; Golden B
    Ann Ophthalmol; 1971 Aug; 3(8):877-82. PubMed ID: 5005929
    [No Abstract]   [Full Text] [Related]  

  • 6. Rifampicin, a general review.
    Binda G; Domenichini E; Gottardi A; Orlandi B; Ortelli E; Pacini B; Fowst G
    Arzneimittelforschung; 1971 Dec; 21(12):1907-77. PubMed ID: 4945790
    [No Abstract]   [Full Text] [Related]  

  • 7. Mechanism of action of a rifamycin derivative (AF-013) which is active on the nucleic acid polymerases insensitive to rifampicin.
    Riva S; Fietta A; Silvestri LG
    Biochem Biophys Res Commun; 1972 Dec; 49(5):1263-71. PubMed ID: 4566674
    [No Abstract]   [Full Text] [Related]  

  • 8. [Experimental antitubercular activity of rifampicin, a derivative of rifamycin SV].
    Grumbach F; Rist N
    Rev Tuberc Pneumol (Paris); 1967; 31(6):749-62. PubMed ID: 4988378
    [No Abstract]   [Full Text] [Related]  

  • 9. CGP 4832, a new semisynthetic rifamycin derivative highly active against some gram-negative bacteria.
    Wehrli W; Zimmermann W; Kump W; Tosch W; Vischer W; Zak O
    J Antibiot (Tokyo); 1987 Dec; 40(12):1733-9. PubMed ID: 2448280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of RNA Polymerase by Rifampicin and Rifamycin-Like Molecules.
    Mosaei H; Zenkin N
    EcoSal Plus; 2020 Apr; 9(1):. PubMed ID: 32342856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent trends in rifamycin research.
    Lal R; Lal S
    Bioessays; 1994 Mar; 16(3):211-6. PubMed ID: 7513153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rifampin.
    Sanders WE
    Ann Intern Med; 1976 Jul; 85(1):82-6. PubMed ID: 937928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmaceutical view of rifampicin (author's transl)].
    Tsutsumi S; Sakamoto Y; Gido S
    Repura; 1974; 43(1):1-7. PubMed ID: 4610307
    [No Abstract]   [Full Text] [Related]  

  • 14. Characterization of Tunisian Mycobacterium tuberculosis rifampin-resistant clinical isolates.
    Soudani A; Hadjfredj S; Zribi M; Masmoudi A; Messaoud T; Tiouri H; Fendri C
    J Clin Microbiol; 2007 Sep; 45(9):3095-7. PubMed ID: 17652484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of the rifamycin dimers on the activities of nucleic acid polymerases from various sources. Relation between lipophily and toxicity.
    Talpaert-Borlé M; Campagnari F; Discenza G
    J Antibiot (Tokyo); 1975 Aug; 28(8):580-9. PubMed ID: 1158783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Molecular mechanisms of mycobacterium tuberculosis strains resistance to rifampicin and isoniazid].
    Stepanshina VN; Panfertsev EA; Mitrofanova GN; Korobova OV; Stepanshin IuG; Shemiakin IG; Medvedeva IM
    Probl Tuberk; 2000; (1):32-6. PubMed ID: 10750428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The bacteriological principles of tuberculosis treatments].
    Grosset J
    Rev Prat; 1979 Jun; 29(33):2645-50. PubMed ID: 113863
    [No Abstract]   [Full Text] [Related]  

  • 18. A Mycobacterium leprae isolate resistant to dapsone, rifampin, ofloxacin and sparfloxacin.
    Matsuoka M; Kashiwabara Y; Namisato M
    Int J Lepr Other Mycobact Dis; 2000 Dec; 68(4):452-5. PubMed ID: 11332288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cutting costs on mono-resistant tuberculosis diagnosis could eventually end up being more expensive.
    Rouzaud F; Robledo J
    Indian J Med Microbiol; 2010; 28(4):412-3. PubMed ID: 20966587
    [No Abstract]   [Full Text] [Related]  

  • 20. Rifampin in dermatology.
    Tsankov N; Angelova I
    Dis Mon; 2004 Jul; 50(7):369-80. PubMed ID: 15280868
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.